6 Dimensions Capital

INVESTMENT AND MANAGEMENT TEAM

Leon Chen (PhD)

CEO & Founding Partner

Dr. Chen is Founder and Managing Partner of Frontline BioVentures. Leon has over 20 years of experience in the Life Sciences industry in China and the U.S. as a venture capitalist, senior management executive, entrepreneur, and scientific inventor.

Erdong Hua

Partner

Mr. Hua is a Partner of Frontline BioVentures. He joined the team in 2012 with over 10 years of dedicated experience in medical/healthcare, venture capital investment and financial industries.

Rebecca Zhu

Partner

Qin Xie (PhD)

Partner

Colin Wang (PhD)

Partner

Hannes Smárason

Senior Managing Director

Rebecca Zhu (CFA)

Managing Director

Ms. Zhu joined Frontline BioVentures in 2014 with over 6 years of investment experience in healthcare industry. Prior to Frontline BioVentures, Ms. Zhu was Analyst of Power Pacific Corporation (member of Power Corporation of Canada), specializing in research and investment in publicly traded healthcare companies listed in Shanghai, Shenzhen and Hong Kong Stock Exchange.

Qin Xie (PhD)

Executive Director

BD Manager and Board Secretary, Hisun Pfizer Lin Ni (PhD) JV
Senior Investment Manager, Shanghai Pharma.
D Phil. in Neuropharmacology from University of Oxford
BM in Clinical Medicine from Xi’an Jiaotong University

Wei Zhao (PhD)

Executive Director

Ex-Senior Life Sciences Specialist, L.E.K. Consulting
Postdoctoral fellow, Massachusetts Eye and Ear Infirmary / Harvard Medical School
PhD in Neuroscience, Northwestern University

Jianwei Yuan

Vice President

Ex-Senior Investment Manager for Medical Device M&A at Fosun Pharma
Ex-Scientist, Pharmaceutical R&D in CNS at Glaxo Smith Kline
MS from Shanghai Institute of Biological Sciences, MBA from Fudan University, CFA Level I

Jie Zhang (PhD)

Vice President

Ex-Principal Scientist, Infectious Disease Research, WuXi AppTec
Ex-Institute Pasteur, CNRS France
MS in systemic biology in University of Paris
PhD in Pathology and Cell Biology from University of Montreal

Corrine Chen

Vice President

Ms. Corrine Chen joined Frontline BioVentures in 2017 with over 5 years of investment and professional service experience. Ms. Chen started her career in KPMG, leading and participating in several annual audit engagements of China and HK listed companies, and several NASDAQ/NYSE/HKEX IPO audit engagements as an Assistant Manager in audit department.

Leo Yan

Senior Associate

Mr. Leo Yan joined Frontline BioVentures in 2016 with over 5 years of investment experience in healthcare industry. Before joining Frontline BioVentures, Mr. Yan was Senior Investment Manager of Global Healthcare Service Team in Fosun Health Holdings, a department under Fosun International (00656.HK).

Jia Sun(PhD)

Associate

OPERATION TEAM

Christina Chung

Chief Financial Officer

Based in Hong Kong, Ms. Christina Chung is the Chief Financial Officer of Frontline BioVentures. Christina has over 13 years of hands-on professional experience in the finance and accounting field. Prior to Frontline BioVentures, Christina was the Associate Director of Fidelity Growth Partners Asia (Fidelity) between 2009 to 2013, responsible for the finance reporting, valuation and portfolio management activities.

VENTURE PARTNERS

Hongye Sun

PhD

Greg Verdine

PhD

Dong Wu

MBA

Norman Chen

MBA

AFFILIATE MEMBERS

Wei Li

PhD

Ching Zhu

PhD

ADVISORS

Allen CHAO

PhD
Chairman and Managing Partner Newport Healthcare

Jason SUN

PhD
Founder and Chairman Curative Medical

Quanlu ZHENG

Prof.
Chairman Neusoft Medical

Xiaoliang Sunney XIE

PhD
Mallinckrodt Professor Harvard University

Team

INVESTMENT AND MANAGEMENT TEAM

Leon Chen (PhD)

Erdong Hua

Rebecca Zhu

Qin Xie (PhD)

Colin Wang (PhD)

Hannes Smárason

Rebecca Zhu (CFA)

Qin Xie (PhD)

Wei Zhao (PhD)

Jianwei Yuan

Jie Zhang (PhD)

Corrine Chen

Leo Yan

Jia Sun(PhD)

OPERATION TEAM

Christina Chung

Jin Wang

Vivian Li

Richard Li

VENTURE PARTNERS

Hongye Sun

Greg Verdine

Dong Wu

Norman Chen

AFFILIATE MEMBERS

Wei Li

Ching Zhu

ADVISORS

Allen CHAO

Jason SUN

Quanlu ZHENG

Xiaoliang Sunney XIE

Curon Biopharmaceutical incubated by 6 Dimensions Capital Completed A USD $150 Million First Round of Financing

Lyvgen Biopharma completing a USD $30 million Series B funding round, which is led by 6 Dimensions Capital

Centrexion Therapeutics Announces First Patient Dosed in Phase 3 Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain

Hongye Sun

Venture Partner at 6 Dimensions Capital

Hongye Sun

Venture Partner at 6 Dimensions Capital

San Mateo, California

Overview

Work Experience

6 Dimensions Capital

Venture Partner

2020 - Current

WuXi NextCODE

CTO

2018 - 2020

CTO of WuXi NextCODE and Head of China

2015 - 2018

WuXi AppTec

VP of Platform Technologies and COO of Genome Center

2011 - 2015

Life Technologies

Principal Scientist

2001 - 2011

Education

Peking University

Doctor of Philosophy - PhD

1989 - 1992

Relevant Websites